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Abstract
The purpose of this literature review is to determine if there is a statistical difference in the safety
and efficacy between romosozumab, the prototypical drug in the new drug class sclerostin
inhibitors, versus alendronate, the prototypical bisphosphonate, in the treatment of
postmenopausal osteoporosis. A comprehensive literature review was performed searching three
databases, including PubMed, EMBASE, and Access Medicine from the last five years. Works
chosen for review were limited to articles published in English, full-text articles, clinical trials,
randomized control trials, systematic reviews, and meta-analyses. Items were excluded after
reviewing abstracts due to material not directly comparing the treatment modalities. The research
presented shows beneficial evidence of bone formation and retention of bone density with
treating postmenopausal women with osteoporosis with romosozumab for two years, followed by
bisphosphonate therapy. However, the risks and benefits of this treatment regimen must be taken
into consideration for each patient. Taking extra caution in starting romosozumab treatment in
patients with cardiovascular health issues. Healthcare providers must take a thorough medical
history and decide in collaboration with the patient about their treatment for osteoporosis.
Current research on sclerostin inhibitors does show promise in the treatment of osteoporosis.
However, more research still needs to be done to determine safety in patients with cardiovascular
health issues.
Keywords: romosozumab, alendronate, postmenopausal, female, human, safety, efficacy
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Introduction
Romosozumab is the prototypical drug in a new class of medication, sclerostin inhibitors,
which have been found to decrease fractures in postmenopausal women with osteoporosis.
Romosozumab was approved by the Federal Drug Administration (FDA) in April 2019 (Food
and Drug Administration, 2019). Romosozumab, a monoclonal antibody, inhibits sclerostin, and
rapidly increases BMD by increasing bone formation and decreasing bone resorption (Ishibashi
et al., 2017). Alternatively, Alendronate, the prototypical drug for bisphosphonates, has been
around since the 1960s for the treatment of osteoporosis in postmenopausal women (Blume and
Curtis, 2011). Alendronate works by inhibiting osteoclast-mediated bone resorption (Blume and
Curtis, 2011). Osteoporosis in postmenopausal women is an essential issue because 10 million
Americans have osteoporosis, and 80% of them are postmenopausal women (National
Osteoporosis Foundation, 2019). This is a crucial issue because the annual medical cost spent on
osteoporosis-related fractures in the United States is $16 billion (Blume & Curtis, 2011). Some
patients with minimal health problems experience falls that cause devastating fractures due to
their osteoporosis, which can leave them with significant medical bills and debilitating injuries.
The purpose of this scholarly project is to answer the question of whether romosozumab,
the prototypical sclerostin inhibitor; or alendronate, the prototypical bisphosphonate, is more
effective in decreasing fractures in the treatment of osteoporosis in postmenopausal women,
along with a comparison of the adverse effect profile of each medication in this population.
Statement of the Problem
Osteoporosis in postmenopausal women is a very pressing issue in healthcare throughout
the United States, as it affects numerous current patients and will continue to affect patients in
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the future. There are many different approaches to the treatment of postmenopausal osteoporosis.
Alendronate has been considered the “tried and true” treatment. However, romosozumab, the
prototypical medication in the new class of drugs, sclerostin inhibitors, is now FDA approved in
the treatment of osteoporosis in postmenopausal women. A comparison of efficacy and adverse
effects will determine which medication is preferred for the treatment of osteoporosis in
postmenopausal women.
Research Question
Is there a statistical difference in safety and efficacy between romosozumab, the
prototypical drug in the new drug class sclerostin inhibitors, versus alendronate, the prototypical
bisphosphonate, in the treatment of postmenopausal osteoporosis?
Methods
A comprehensive literature review was performed of PubMed, EMBASE, and Access
Medicine. Keywords, MESH terms, and filters were used to define a set of literature discussing
the efficacy and adverse effects of romosozumab and alendronate in the treatment of
osteoporosis in postmenopausal women. Articles for theme one and three were found by using
“romosozumab postmenopausal” as search terms; this resulted in 70 articles. The search was
narrowed by limiting the search to the last five years, full text, “female,” and “English” articles
along with the MESH term “humans.” Results for theme one was completed by adding “safety”
to the search terms. After review of the articles, two were excluded due to the information not
being relevant, resulting in four articles. Results for theme three were achieved by adding
“efficacy” to the search terms. After review of the articles, three articles were excluded due to
the information not being relevant, resulting in six articles.
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Articles for theme two and four were found by using “alendronate postmenopausal” as
search terms, this resulted in 1,675 articles. The search was narrowed by limiting the search to
the last five years, full text, “female,” “English,” and “clinical trial article” filters. The MESH
term “humans” was added to the search resulting in 160 articles. Results for theme two were
completed by adding “safety” to the search terms. After reviewing the articles, five articles were
excluded due to not being relevant, and two articles were added from other themes because the
content fits better with theme two, resulting in four final articles. Results for theme four were
completed by adding “efficacy” to the search term. After reviewing the articles, seven articles
were excluded due to them not being relevant, and one article was added from a different theme
because the content fits better in theme four, resulting in three final articles.
Articles for theme five were found by using “romosozumab alendronate” as search terms,
resulting in 28 articles. The search was narrowed by filtering to “last five years,” “English,”
“female,” and “journal article” to the filters. The search was further narrowed by adding
“humans” as a MESH term. After reviewing the articles, one article was excluded due to the
content not being relevant, and one article was added from another theme due to the content
being more fitting with theme five, resulting in six final articles. In total, there were 16 articles
found for this literature review, with some articles used in multiple themes.
Literature Review
A review of the literature shows that both romosozumab and alendronate have been
extensively researched and determined to be safe and efficient in the treatment of
postmenopausal females with osteoporosis. A review of the research shows that treatment with
romosozumab or alendronate reduces fracture risk and increases bone mineral density (BMD).
However, with different mechanisms of action, one may be statistically superior in safety and
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efficacy. Studies are limited to those published within the last five years to incorporate the
newest research on this topic.
Safety of Romosozumab, Prototypical Sclerostin Inhibitor, in Postmenopausal Women
A meta-analysis by Bandeira, Lewiecki, and Bilezikian (2017) investigates the efficacy
and side effects of romosozumab. Amongst the studies, some patients developed antiromosozumab antibodies with a higher incidence in higher doses. There were no clinical side
effects in patients who developed antibodies (Bandeira et al., 2017). Mild side effects reported
by participants were similar between the romosozumab and placebo groups. The most common
side effects related to romosozumab in the phase III trial were dose-related to 210 mg injection
and include arthralgia, nasopharyngitis, and back pain (Bandeira et al., 2017). Injection site
reactions were also observed more frequently than with the placebo. Serious side effects of
romosozumab included 6.8% participants experiencing hypersensitivity reaction, < 0.1%
osteonecrosis of the jaw (ONJ), and < 0.1% atypical femur fracture (Bandeira et al., 2017). Since
romosozumab is a bone-forming agent, there was concern about cancer formation. However,
there was no difference between the romosozumab and placebo groups. Limitations include
having limited data on the occurrence of adverse effects.
A phase II study conducted by Ishibashi et al., (2017) compared osteoporosis treatment
with romosozumab 70 mg, 140 mg, and 210 mg once-monthly injections, along with a placebo
group for 12 months. The study included postmenopausal Japanese women with osteoporosis.
Requirements included having a lumbar spine, total hip, or femoral neck dual-energy X-ray
absorptiometry (DEXA) T-score ≤ -2.5. Participants were excluded if they had any previous
osteoporosis treatment or underlying metabolic disease. The study was double-blind, placebocontrolled, and dose-ranging. Patients in each treatment group also received ≥ 500 mg calcium
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and ≥ 600 IU vitamin D. DEXA scans were completed at 6 and 12 months to determine percent
change from baseline BMD. Bone turnover markers in the serum include procollagen type 1 Nterminal propeptide (P1NP) and C-terminal telopeptide of type 1 collagen (βCTX); these were
tested at multiple visits. The placebo group reported 6.3% serious adverse events, and
romosozumab reported 5.3% serious side effects; 9.5% in the 70 mg group, 3.2% in the 140 mg
group, and 3.2% in the 210 mg group (Ishibashi et al., 2017). The placebo group experienced
68.3% mild adverse events and romosozumab experienced 74.6% mild adverse events; 77.8%
romosozumab 70 mg, 71.4% romosozumab 140 mg, and 74.6% romosozumab 210 mg (Ishibashi
et al., 2017). According to Ishibashi et al., no fatal adverse events were reported for any of the
groups. However, three participants had to discontinue the study due to adverse events (Ishibashi
et al., 2017). Two of these participants were in the romosozumab 70 mg monthly group, and
experienced dizziness and subarachnoid hemorrhage, and one was in the romosozumab 210 mg
monthly group and experienced hypochondriasis (Ishibashi et al., 2017). Ishibashi et al. reported
that one member of each group experienced a fracture of the rib, radius, foot, or wrist. There
were no events of ONJ or femur fractures (Ishibashi et al., 2017). Participants in the
romosozumab groups did experience antibody development in 31% of the 70 mg group, 36.5%
in the 140 mg group, and 23.8% in the 210 mg group (Ishibashi et al., 2017). Only two of the
patients tested positive for antibodies one year after the last dose of romosozumab was given,
and there were no adverse effects related to the antibodies (Ishibashi et al., 2017). The strengths
of the study include eliminating pre-disposing health issues that would skew results. The
limitations of this study are that it only included Japanese women, and the dose of calcium and
vitamin D was not consistent between participants. Both of these factors could have significantly
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skewed the results of the study as genetics, as well as calcium and vitamin D supplementation,
play an important role in osteoporosis.
A systematic review and meta-analysis performed by Liu et al., (2018) of randomized
control trials evaluate the safety and efficacy of romosozumab in the treatment of
postmenopausal women with osteoporosis. According to Liu et al., there is not a significant
difference in the incidence of adverse events in patients treated with romosozumab compared to
placebo (95% CI, p = 0.93) and alendronate (95% CI, p = 0.02). A limitation of this study is that
the follow-up time was short, only 12 months; the safety of romosozumab needs a longer
duration of follow up to confirm the results of adverse events.
A meta-analysis by Romosozumab (Evenity) for Postmenopausal Osteoporosis (2019)
looked at studies comparing romosozumab to other therapies, including placebo and alendronate.
Arthralgia and headaches were the most reported adverse effects with romosozumab
(Romosozumab (Evenity) for Postmenopausal Osteoporosis, 2019). Romosozumab was
associated with three occurrences of ONJ and three occurrences of atypical femoral fractures. It
was found by Romosozumab (Evenity) for Postmenopausal Osteoporosis that romosozumab may
increase the risk of myocardial infarctions, stroke, or cardiovascular death and, therefore, should
not be used in patients who have had a myocardial infarction or stroke within the previous year.
According to Romosozumab (Evenity) for Postmenopausal Osteoporosis, clinical trials showed
an increase of cardiovascular adverse effects with romosozumab compared to alendronate but
similar events when comparing romosozumab to placebo. Neutralizing antibodies to
romosozumab did develop, but it was not determined if the antibodies reduced efficacy or not
(Romosozumab (Evenity) for Postmenopausal Osteoporosis, 2019). A limitation of this article
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that should be addressed with future research is if anti-romosozumab antibodies change the
effectiveness of romosozumab or not.
Safety of Alendronate, Prototypical Bisphosphonate, in Postmenopausal Women
A study by Hassler, Gamsjaeger, Hofstetter, Brozek, Klaushofer, and Paschalis (2014)
compared the micro-spectroscopic analysis of iliac crests biopsies from postmenopausal
osteoporosis patients that were treated with alendronate for ten years compared to five years. It
revealed that there were minimal alterations in bone material properties when comparing fiveyear and ten-year alendronate therapy (Hassler et al., 2014). This suggests that prolonged
reduction in bone turnover with ten years of alendronate therapy is unlikely associated with
adverse effects on bone material. However, the continued bone turnover reduction has been
proposed to be a possible mechanism of rare adverse effects of bisphosphonates, such as ONJ
and atypical femoral fractures. A limitation of this study includes not having a placebo group for
either of the five-year or ten-year alendronate groups, which makes the evidence less convincing
since there is not a fair treatment comparison.
An article by Iwamoto et al. (2015) outlines a six-month, cluster-randomized, open-label,
multicenter, crossover trial. This study compared monthly bisphosphonate therapy versus weekly
bisphosphonate therapy in Japanese patients with osteoporosis. Upper gastrointestinal tract
effects were the most common side effects noted, with 7.4% participants from the monthly
injections and 10.7% participants from the weekly injections (Iwamoto et al., 2015). Iwamoto et
al. concluded that there is a strong preference for the monthly injections versus weekly injections
with no statistical difference in adverse effects. The limitations of this study are that the sample
size may not have been sufficient to draw accurate conclusions and that the number of patients in
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each group differed. Another limitation is that different types and doses of bisphosphonates were
used in the weekly and monthly regimens.
Milat and Ebeling (2016) performed a narrative review of postmenopausal osteoporosis
treatment options. Treatment with alendronate reduces vertebral fracture risk by 48% compared
with the placebo (Milat & Ebeling, 2016). The most common adverse effect of oral
bisphosphonate treatment is gastrointestinal symptoms, including reflux, esophagitis, gastritis,
and diarrhea (Milat & Ebeling, 2016). Oral bisphosphonates should not be avoided in patients
with active upper gastrointestinal disease, dysphagia, or achalasia. According to Milat and
Ebeling, the most common adverse effect of intravenous bisphosphonates is flu-like symptoms
such as fever, myalgia, headache, and arthralgia. Bisphosphonates can also lower serum calcium
but are uncommon without underlying vitamin D deficiency (Milat & Ebeling, 2016). Milat and
Ebeling found that bisphosphonates should not be recommended in patients with a creatinine
clearance below 35 mL/min. ONJ and atypical femoral fractures have occurred but are less
frequent (Milat & Ebeling, 2016). The risk of ONJ in patients taking oral bisphosphonates is 1 in
10,000 to 1 in 100,000 patients per year (Milat & Ebeling, 2016). It was also found by Milat and
Ebeling that over suppression of bone remodeling could lead to microdamage accumulation,
which could lead to increased fragility. Atypical femoral fractures appear to be more frequent
(113 in 100,000 patients per year) in patients who have been exposed to long-term
bisphosphonate therapy (seven to eight years) (Milat & Ebeling, 2016). However, the risk of
sequential atypical femoral fracture reduced 12 months after cessation of bisphosphonate
treatment (Milat & Ebeling, 2016). Limitations of this article include only studying participants
of Australian ethnicity, which can significantly skew the results as genetics play an essential role
in the pathogenesis of osteoporosis.
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Zhang et al. (2015) performed a randomized, open-label, active comparator-controlled
study of Chinese postmenopausal women with osteoporosis. The study compared the efficacy of
alendronate/vitamin D5600 weekly infusions and calcitriol oral daily intake. The
alendronate/vitamin D5600 group had 14% reported adverse events, and the calcitriol group had
7.4% reported adverse events (Zhang et al., 2015). The most frequently reported adverse event
was upper abdominal pain (Zhang et al., 2015). According to Zhang et al., drug-related adverse
events that lead to discontinuation of therapy occurred in 2.8% of the participants in the
alendronate/vitamin D5600 and 0% of the participants in the calcitriol group. Zhang et al.
reported that hypercalciuria after 12 months of treatment was 8.4% in the alendronate/vitamin
D5600 versus 13.9% in the calcitriol group but was not statistically significant (p > 0.05). A
limitation of this study was that it was an open-label design that allowed participants to know
what medication they were taking.
Efficacy of Romosozumab, Prototypical Sclerostin Inhibitor, in Postmenopausal Women
A meta-analysis by Bandeira et al. compares romosozumab’s efficacy and side effects
compared to older medications and placebo groups. Bisphosphonates are the most common
treatment for osteoporosis; this medication class is effective in reducing fracture risk, has low
cost, and higher availability than newer medications such as romosozumab (Bandeira et al.,
2017). In one study, Bandeira et al. found that romosozumab had a significant increase in bone
formation markers, procollagen type 1 amino-terminal propeptide (P1NP), bone alkaline
phosphatase (BAP), and osteocalcin along with a decrease in bone resorption marker, Ctelopeptide of type I collagen (βCTX-I). Bandeira et al. reported that the changes seen with the
biochemical markers were dose-dependent, and βCTX-1 decreased by 50% (p < 0.01) compared
to placebo. In another study by McClung et al., an increase of 100% P1NP after one month of
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210 mg romosozumab monthly subcutaneous injections (p < 0.04) compared to placebo but did
return to baseline between two and nine months after discontinuation. A decrease of 50% βCTXI occurred within the first week after 210 mg subcutaneous dose of romosozumab (p < 0.04)
compared to placebo but did remain below baseline after one year with monthly doses (Bandeira
et al., 2017). A phase III study showed an increase of 150% P1NP after monthly injections of
210 mg romosozumab (p < 0.001) compared to placebo, with the return to baseline at nine
months (Bandeira et al., 2017). According to Bandeira et al., this study also showed evidence
that βCTX-I decreased 50% and remained below baseline at 12 months (p < 0.001) compared to
placebo. Bandeira et al. report that phase I studies showed a dose-dependent increase in BMD of
5.3% at the lumbar spine and 2.8% at the total hip after administration of 10 mg/kg
romosozumab (p < 0.01) for both compared to placebo. Bandeira et al. found that in phase II
studies, romosozumab showed a significant increase in BMD at the lumbar spine, femoral neck,
and total hip (p < 0.001 compared to placebo, alendronate, and teriparatide). In a phase III
postmenopausal study, women with osteoporosis were randomized into two groups, one to
receive romosozumab 210 mg monthly injections and placebo (Bandeira et al., 2017). The first
year each received either romosozumab or placebo injections; after one year, both groups were
switched to denosumab 60 mg subcutaneous injections every six months (Bandeira et al., 2017).
After one year, romosozumab showed a 73% reduction in new vertebral fractures compared to
placebo (p < 0.001), shown in figure 1 (Bandeira et al., 2017). There was also a 36% decrease in
clinical fractures (p = 0.008), as shown in figure 2 (Bandeira et al., 2017).
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Figure 1. New vertebral fractures after 1 year. Romosozumab with
a 73% reduction in new vertebral fractures compared to placebo.
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Figure 2. New clinical fractures after 1 year. Romosozumab with a
35% reduction in new clinical fractures compared to placebo.

Figures 1 and 2 From “Romosozumab for the treatment of osteoporosis,” by L. Bandeira, M. Lewiecki, and P. Bilezikian, 2017, Expert
Opinion on Biological Therapy, volume 17, p. 259. Copyright 2017 Taylor & Francis Group.

Bandeira et al. report that after two years, there was a decrease of 75% new vertebral fractures in
the romosozumab/denosumab group compared to the placebo (p = 0.002). Bandeira et al. found
no statistical difference in clinical fractures when comparing both groups at the end of two years
(p = 0.1). However, Bandeira et al. found that when Latin American participants were excluded,
there was a statistical difference in clinical fractures when comparing the
romosozumab/denosumab group compared to the placebo (p < 0.04). A limitation of this study is
that 46% of the participant group was Latin American ethnicity, which baseline 10-year risk of
osteoporotic fractures is 8.7% in Latin Americans compared to 17% everywhere else in the
world. This limitation skewed the data toward a nonsignificant reduction in non-vertebral
fractures due to an increased Latin American participant being a part of the placebo group.
A metanalysis by Bhattacharyya, Pal, and Chattopadhyay (2018) investigates the efficacy
of romosozumab. It was found by Bhattacharyya et al. that romosozumab increased BMD in
postmenopausal women in the lumbar spine by 13.3%, total hip by 6.8%, and femoral neck by
5.2% from baseline, but was not effective in increasing the BMD in the wrist or radius. Overall,
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treatment with romosozumab 210 mg monthly subcutaneous injections for 12 months reduced
the new vertebral fracture risk ratio to 0.27 and nonvertebral fracture risk to 0.75 (Bhattacharyya
et al., 2018). Bone resorption markers (βCTX) decreased by 50% below the baseline during the
first week and remained below baseline throughout the 12-month treatment course
(Bhattacharyya et al., 2018). A limitation of this study is that it only compared treatment with
romosozumab to blosozumab, another sclerostin inhibitor, and did not have a placebo treatment
group.
Horne, Mihov, and Reid (2018) performed a meta-analysis of the effects of romosozumab
treatment followed by denosumab treatment in postmenopausal women with a T-score of -2.5 to
-3.5 at the total hip and femoral neck. This study by Horne et al. found that spine BMD was
17.3% above baseline at the end of a 12-month trial that involved 210 mg monthly injections
with romosozumab (CI 61%). When this treatment was followed by denosumab for 12 months,
BMD continued to be 12.3% above baseline (CI 85%), which is a 73% retention of treatment
benefit (Horne et al., 2018). Total hip BMD was increased by 10.7% at the end of the 12-month
trial with romosozumab (CI 77%) and continued to be 9.2% above baseline after another 12
months of denosumab treatment (CI 98%), which is an 87% retention of treatment effect (Horne
et al., 2018). Horne et al. found that participants who did not receive denosumab treatment after
the completion of romosozumab treatment lost 80-90% of BMD, suggesting a rapid off-set of
action. A limitation of this study is that the participants started bisphosphonate therapy at varying
times after ending romosozumab treatment; some started the month after, and some did not begin
until four months after stopping romosozumab.
This phase II study by Ishibashi et al. compared osteoporosis treatment with
romosozumab 70 mg, 140 mg, and 210 mg once-monthly injections, along with a placebo group.
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Romosozumab is a monoclonal antibody that inhibits sclerostin and rapidly increases BMD by
increasing bone formation along with decreasing bone resorption. The study included
postmenopausal Japanese women with osteoporosis. Requirements for participants included
having a lumbar spine, total hip, or femoral neck DEXA T-score ≤ -2.5. Participants were
excluded if they had any previous osteoporosis treatment or underlying metabolic disease. The
study was double-blind, placebo-controlled, and dose-ranging. Women were randomly chosen to
receive placebo or romosozumab 70 mg, 140 mg, or 210 mg subcutaneous once-monthly
injections for 12 months. Patients in each treatment group also received ≥ 500 mg calcium and ≥
600 IU vitamin D. DEXA scans were completed at six and 12 months to determine percent
change from baseline BMD. Serum bone turnover markers procollagen type 1 N-terminal
propeptide (P1NP) and C-terminal telopeptide of type 1 collagen (βCTX) were tested at multiple
visits. Ishibashi et al. found that all participants receiving romosozumab significantly increased
BMD at the 12-month DEXA scan compared to the placebo (p = 0.01, CI 95%). BMD increased
from baseline to 12 months, with romosozumab 210 mg monthly injections by 16.9% at the
lumbar spine, 4.7% at the total hip, and 3.8% at the femoral neck (Ishibashi et al., 2017).
Romosozumab 210 mg monthly injections showed significantly higher efficacy in increasing
BMD compared to placebo and the lower (70 mg and 140 mg) monthly romosozumab injections
(Ishibashi et al., 2017). According to Ishibashi et al., all doses of romosozumab also significantly
increased the levels of bone formation marker P1NP and reduced levels of bone resorption
marker βCTX by week one compared to placebo (p 0.001, CI 95%). However, Ishibashi et al.
found in the romosozumab 210 mg monthly injection group, the P1NP levels peaked at one
month and fell below placebo levels by 12 months, but βCTX levels were the lowest at week one
and remained below placebo through the 12-month mark. The strengths of the study include
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eliminating pre-disposing health issues that would skew results. The limitations of this study
were that it only included Japanese women and that the dose of calcium and vitamin was not
consistent between participants.
This systematic review and meta-analysis by Liu et al. of randomized control trials
evaluate the safety and efficacy of romosozumab in the treatment of postmenopausal women
with osteoporosis. Amongst analyzing six trials it was found that romosozumab had a
significantly lower risk of new vertebral fractures (95% CI, p= 0.005), non-vertebral fractures
(95% CI, p < 0.0001), and hip fracture (95% CI, p= 0.0004) compared to placebo, alendronate,
and teriparatide (Liu et al., 2018). BMD was significantly increased with romosozumab
treatment versus placebo (Liu et al. 2018). According to Liu et al. lumbar spine had a weighted
mean difference (WMD) increase of 12.33 (95% CI, p < 0.00001), total hip WMD increase of
5.09 (95% CI, p < 0.00001), and femoral neck WMD increase of 4.70 (95% CI, P < 0.00001).
The largest gains in BMD were dose-dependent, the highest increase of BMD seen in the
participants receiving romosozumab 210 mg monthly injections (Liu et al., 2018). A more recent
study found that romosozumab treatment after previous bisphosphonate treatment continued to
show significantly increased BMD at the lumbar spine, total hip, and femoral neck 12 months
after the switch from a bisphosphonate to romosozumab therapy (Liu et al., 2018). A limitation
of this study is that the follow-up time was short, only 12 months.
In this 12-month, phase I clinical study by Makras, Delaroudis, and Anastasilakis (2015)
of postmenopausal females with low BMD, it was found that bone formation markers increased,
and bone resorption markers decreased dose-dependently following a single subcutaneous
injection of romosozumab. Makras et al. found the maximum increase of bone formation
markers and decrease in bone resorption occurred around day 15 following the injection and

POSTMENOPAUSAL OSTEOPROSIS TREATMENT

19

returned to baseline after two months. Phase II studies showed that romosozumab increased
BMD after 12 months of monthly injections at the lumbar spine by 11.3%, total hip by 4.1%, and
femoral neck by 3.7%, but no increase in BMD at the distal radius (Makras et al., 2015). The
increase in BMD was found to be dose-dependent, with the highest increase in the participants
receiving romosozumab 210 mg subcutaneous injections (Makras et al., 2015). According to
Makras et al., these results are reported to be considerably higher than observed in phase II
clinical studies for alendronate (p < 0.001). A limitation of this study is that the participant's
baseline BMD varied between low BMD to osteoporotic levels.
Efficacy of Alendronate, Prototypical Bisphosphonate, in Postmenopausal Women
This prospective open-label randomized study by Cesareo et al. (2014) compared BMD
of a treatment group of alendronate/cholecalciferol (70 mg- 2800 IU) weekly oral dosing versus
a control group of vitamin D (2800 IU) weekly oral dosing alone over 12 months. The
participants were all postmenopausal women with osteoporosis (T-score -2.5) and with primary
normo-calcemic hyperparathyroidism (NPHPT). BMD was measured using DEXA scans at L1L4, total hip, and femoral neck. Cesareo et al. found that after 12 months, BMD increased
significantly from baseline at the lumbar spine, femoral neck, and total hip in the treatment group
(p= 0.001). The most considerable increase of BMD was at the lumbar spine, with a rise of 4.7%
in the treatment group (Cesareo et al., 2014). According to Cesareo et al., the control group
resulted in a significant decrease in BMD compared to baseline after 12 months of treatment at
all sites (p = 0.001). Cesareo et al. found that bone turnover markers (BTM) significantly
decreased in the treatment group compared to the control group at three months and six months
(p < 0.001). Both the treatment and control groups did not affect serum or urinary calcium
(Cesareo et al., 2014). Limitations of this study include that it was not a double-blind trial, and
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the sample size was small, with only 30 participants. It also only included participants with
norm-calcemic primary hyperparathyroidism, which is a small subset of patients with
osteoporosis.
A study by Hassler et al. compared the micro-spectroscopic analysis of iliac crests
biopsies from postmenopausal osteoporosis patients that were treated with alendronate for ten
years compared to five years. It was found by Hassler et al. that 10-year therapy with alendronate
restores material bone indices to premenopausal non-osteoporotic values. Both alendronate
treated groups had higher values in both cancellous and cortical bone (Hassler et al., 2014). A
limitation of this study includes not having a placebo group for either of the five years or tenyear alendronate groups.
A randomized, open-label, active comparator-controlled study by Zhang et al. of Chinese
postmenopausal women with osteoporosis. The study compared the efficacy of
alendronate/vitamin D5600 weekly infusions and calcitriol oral daily intake. BMD was assessed
via DEXA. Zhang et al. found that alendronate/vitamin D5600 had a more significant increase in
lumbar spine BMD 5.2% versus a 2.3% increase in the calcitriol group at 12 months (p > 0.001).
Zhang et al. also found that alendronate/vitamin D5600 had a more significant decrease in bone
turnover markers compared to the calcitriol group at both six and 12 months (p < 0.001). A
limitation of this study was that it was an open-label design that allowed participants to know
what medication they were taking.
Direct Comparison of Romosozumab and Alendronate
A systematic review by Ferrari (2018) compares romosozumab and alendronate in the
treatment of osteoporosis. Bone formation occurs through two main mechanisms, bone
resorption, and bone remodeling. Romosozumab works by activating the Wnt-β-catenin
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signaling pathway, and alendronate works by inhibiting bone remodeling. Ferrari reports that in
the FRAME trial, postmenopausal women with osteoporosis that were treated with
romosozumab increased spine BMD by 13.3% and hip BMD by 6.8%. Ferrari also found that
romosozumab decreased the risk of vertebral fractures by 73% and clinical fractures by 36%
after 12 months of treatment compared to placebo, which was statistically significant. Ferrari
also discovered a decreased risk of non-vertebral fractures by 25% with romosozumab, but this
was not statistically significant. According to Ferrari, the ARCH trial found that romosozumab
increased BMD 2.5-fold at the spine and 2-fold at the hip after 12 months of treatment compared
to alendronate. Ferrari also found that vertebral fracture was 37% lower with romosozumab
treatment than alendronate at 12 months of treatment and 48% lower after 24 months of
treatment. At the end of 33 months, the participants treated with romosozumab had 27% less
clinical fractures, 19% less non-vertebral fractures, and 38% fewer hip fractures compared to the
participants who received treatment with alendronate (Ferrari, 2018). The ARCH trial also noted
that participants who were treated with romosozumab had an increased incidence of severe
cardiovascular events compared to the alendronate treatment group. Still, it remains unclear if
this adverse event is related to sclerostin inhibition or if it is due to the older population having
an increased cardiovascular risk (Ferrari, 2018). A limitation of this article is that the duration of
the two studies reviewed only lasted 12 months each. Data is still needed for long-term
comparison of these two medications.
This meta-analysis by Khosla (2017) compares the newer medication romosozumab to a
more traditionally used medication alendronate in the treatment of osteoporosis in
postmenopausal women. Romosozumab is a sclerostin inhibitor that stimulates bone formation
and inhibits bone resorption and increases bone mass, which reduces fracture risk. According to
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Khosla, the ARCH trial randomly assigned postmenopausal women with osteoporosis and
fragility fracture with 12 months of either once monthly romosozumab injections or once-weekly
oral alendronate followed by open-label alendronate in both groups for another 12 months. The
results at the end of the study showed that romosozumab was superior to alendronate in
decreasing new fractures, romosozumab decreased new vertebral fractures by 48%, clinical
fractures by 27% and hip fractures by 38% (Khosla, 2017). In a phase II study, 210 mg oncemonthly injection of romosozumab increased spine BMD by 11.3% in 12 months, compared to a
decrease of 0.1% with placebo and an increase of 4.1% with alendronate (Khosla, 2017).
According to Khosla, adverse events were more severe in participants receiving romosozumab
compared to those receiving alendronate. Khosla reports that cardiovascular events occurred in
2.5% of participants receiving romosozumab, and 1.9% of participants receiving alendronate (CI
95%). Khosla also found that 0.8% of participants receiving romosozumab experienced cardiac
ischemic events compared to 0.3% of the participants being treated with alendronate (CI 95%).
Khosla reports that the FRAME trial did not identify a difference between cardiovascular
adverse events in participants receiving romosozumab compared to placebo groups. With this
information, it is unsure if romosozumab increases cardiovascular adverse events or if
alendronate is cardioprotective. It was also found by Khosla that the women included in the
ARCH trial were less healthy than the women who were involved in the FRAME trial. There
were twice as many cardiovascular adverse events with the control group, alendronate (1.9%), of
the ARCH trial versus the control group, placebo (1.1%), in the FRAME trial (Khosla, 2017).
Even with this information, it is still believed that romosozumab slightly increases the risk of
cardiovascular events in women with multiple co-morbidities. The biologic probability for this is
because of the effect romosozumab has on Wnt signaling, and its role in cardiovascular

POSTMENOPAUSAL OSTEOPROSIS TREATMENT

23

remodeling and sclerostin levels are increased at sites of vascular calcification. A limitation of
this article is that there is still insufficient research on whether romosozumab increases
cardiovascular adverse events or if alendronate is cardioprotective, and that’s why there is a
difference in the adverse event profile.
A phase II multicenter, randomized, and placebo-controlled study by Larsson (2016)
involved postmenopausal women who received romosozumab 70 mg, 140 mg, or 210 mg
subcutaneous injections monthly or every three months for a 12-month duration. These study
groups were compared to 70 mg oral alendronate given once a week, 20 g of teriparatide
subcutaneous injections once daily, and a placebo group for a 12-month duration. Established
treatment for osteoporosis is currently almost exclusively bisphosphonate therapy.
Bisphosphonate therapy has been around longer than any other osteoporosis treatment and is
inexpensive, which also contributes to its dominance in 1st line osteoporosis therapy options.
Bisphosphonates work by blocking osteoclasts from breaking down the bone (Larsson, 2016).
However, Larsson found that all dose levels of romosozumab had a significant increase in BMD.
The most considerable increase being in the participants who received 210 mg romosozumab, in
which the lumbar spine BMD increased 11.3% from baseline (Larsson, 2016). The placebo
group lumbar spine BMD decreased by 0.1% (Larsson, 2016). The alendronate group lumbar
spine BMD increased by 4.1%, and the teriparatide lumbar spine BMD increased by 7.1%
(Larsson, 2016). According to Larsson, biochemical markers for the alendronate group showed a
non-significant increase in the bone formation marker P1NP and no change in the bone
resorption marker βCTX. A similar rise in BMD was also noted in DEXA scans of the hip, and
femoral neck was found by Larsson, with the most significant increase in patients treated with
210 mg romosozumab. There was no difference in increased BMD of the hip or femoral head in
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the alendronate or teriparatide groups (Larsson, 2016). The conclusion of this study revealed that
romosozumab was associated with increased BMD and bone formation, along with decreased
bone resorption. Side effects were equal in rate and type between all treatment groups compared
with the placebo group. A limitation of this study is that the underlying health and age of the
patient population was not considered; the only requirement was being a postmenopausal
woman. This article also only provides evidence that romosozumab increases BMD but does not
have evidence that an increase in BMD will translate into decreased fractures in postmenopausal
osteoporosis patients.
A systematic review and meta-analysis by Liu et al. of randomized control trials in the
evaluation of the safety and efficacy of romosozumab in the treatment of postmenopausal
women with osteoporosis. According to Liu et al. romosozumab significantly increased BMD of
lumbar spine with a weighted mean difference (WMD) of 8.70 compared to alendronate (CI
95%, p < 0.00001), total hip WMD of 3.40 (95% CI, p < 0.00001), and femoral neck WMD 3.20
(5% CI, p < 0.00001). Liu et al. found no significant difference in the incidence of adverse
events in patients treated with romosozumab compared to placebo (95% CI, p = 0.93) and
alendronate (95% CI, p = 0.02). A limitation of this study is that the follow-up time was short;
being only 12 months long, the safety of romosozumab needs a longer duration of follow up to
confirm the results of adverse events.
A meta-analysis by Romosozumab (Evenity) for Postmenopausal Osteoporosis of studies
compares romosozumab to other therapies, including placebo and bisphosphonates such as
alendronate. The ARCH trial compared outcomes of postmenopausal women with osteoporosis
who received romosozumab 210 mg subcutaneous monthly injections for 12 months to
alendronate 70 mg once weekly injections for 12 months (Romosozumab (Evenity) for
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Postmenopausal Osteoporosis, 2019). New vertebral fractures occurred in 6.2% of participants
who received romosozumab and 11.9% who received alendronate, a statistically significant
difference (Romosozumab (Evenity) for Postmenopausal Osteoporosis, 2019). Clinical fractures,
which included nonvertebral and symptomatic vertebral fractures, occurred in 8.7% of
participants receiving romosozumab and 13% who received alendronate, a statistically
significant difference (Romosozumab (Evenity) for Postmenopausal Osteoporosis, 2019). Rates
of nonvertebral and hip fractures were lower with romosozumab compared to alendronate but
were not statistically different (Romosozumab (Evenity) for Postmenopausal Osteoporosis,
2019). Serious cardiovascular events occurred in 2.5% of participants receiving romosozumab
and 1.9% participants receiving alendronate, and therefore was decided that romosozumab
should not be used in patients who have had a myocardial infarction or stroke within the previous
year (Romosozumab (Evenity) for Postmenopausal Osteoporosis, 2019). A limitation of this
article that should be addressed with future research is if anti-romosozumab antibodies change
the efficacy of romosozumab or not.
This systematic review by Song and Lee (2018) compares romosozumab versus
alendronate in the treatment of osteoporosis in postmenopausal women. Sclerostin is expressed
in aortic vascular smooth muscle and up regulated at sites of vascular calcification. Blocking
sclerostin may lead to vascular calcification and result in arterial stiffening and severe
cardiovascular disease (Song & Lee, 2018). Therefore, advanced abdominal aortic calcification
is more common in patients with vertebral fractures. In the ARCH trial, 96% of participants had
vertebral fractures before starting the trial compared to only 18% of participants in the FRAME
trial. (Song & Lee, 2018). According to Song and Lee, the participants in the ARCH trial likely
had more advanced abdominal aortic calcification before the initiation of the study. Song and
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Lee found that postmenopausal women with osteoporosis that were treated for 12 months with
romosozumab followed by alendronate had a significantly lower risk of fracture than the
participants who only received alendronate. Romosozumab has a time-limited bone-forming
effect and has only been studied as a 12-month course of treatment and is not intended for
continuous long-term use (Song & Lee, 2018). A limitation of this article is there is no data
about the evidence that the ARCH trial contained participants who were more prone to
cardiovascular events compared to the FLAME trial.
Discussion
Osteoporosis is a complex disease. There are many risk factors and genetic variations that
make the treatment of osteoporosis challenging to optimize for each patient. The standard
treatment has been bisphosphonates for many years, but with new research, there are now more
options in the treatment of osteoporosis, such as sclerostin inhibitors. The following section is a
discussion of the review of the literature, focusing on answering the question if there is a
statistical difference in the safety and efficacy between romosozumab, the prototypical drug in
the new drug class of sclerostin inhibitors, versus alendronate, the prototypical bisphosphonate,
in the treatment of postmenopausal osteoporosis.
Safety of Romosozumab, Prototypical Sclerostin Inhibitor, in Postmenopausal Women
A useful systematic review and meta-analysis by Liu et al. compared the side effect
profiles of the two most extensive studies of romosozumab, the ARCH, and FRAME trial. Liu et
al. did not find a statistically significant difference in the adverse events between romosozumab,
alendronate, and placebo treatment groups. Similarly, a phase II study conducted by Ishibashi et
al. reported the placebo group having 6.3% serious adverse events and the romosozumab group
having 5.3% serious adverse events, which did not appear to be dose related. The placebo group
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experienced 68.3% mild adverse events compared to romosozumab experiencing 74.6% mild
adverse events, which also did not appear to be dose-related (Ishibashi at el., 2017).
The meta-analysis performed by Bandeira et al. found that some patients who received
romosozumab developed anti-romosozumab antibodies. However, there were no clinical side
effects in the patients who developed the antibodies. Since romosozumab is a bone-forming
agent, there was concern about increasing cancer formation, but Bandeira et al. found there to be
no difference between the romosozumab and placebo groups. Romosozumab (Evenity) for
postmenopausal osteoporosis, identifies that the increased risk of cardiovascular events due to
romosozumab only occurs in patients with a significant cardiac history. The clinical trials
showed an increase of cardiovascular adverse effects with romosozumab compared to
alendronate but similar events when comparing romosozumab to placebo.
In conclusion, there does not appear to be a statistically significant difference in adverse
effects of romosozumab compared to placebo groups. There is not sufficient evidence to
conclude the cardiovascular events of romosozumab compared to placebo groups. This is
something that should be further researched to draw a definite conclusion.
Safety of Alendronate, Prototypical Bisphosphonate, in Postmenopausal Women
Zhang et al. concluded that there is not a statistically significant difference in adverse
effects with the treatment of alendronate plus vitamin D versus vitamin D alone. A narrative
review by Milat and Ebeling found the most common adverse effects of oral bisphosphonate
treatment to be gastrointestinal symptoms and, therefore, should be avoided in patients with
active upper gastrointestinal disease, dysphagia, or achalasia. Milat and Ebeling found the most
common adverse event of intravenous bisphosphonate therapy to be flu-like symptoms. A study
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performed by Iwamoto et al. also found upper gastrointestinal side effects to be the most
common, but not statistically significant, adverse events with bisphosphonate therapy in
Japanese patients with osteoporosis. With more adverse events reported with weekly injections
versus monthly injections.
An analysis of iliac crest biopsies performed by Hassler et al. revealed minimal
alterations in bone material properties when comparing 5-year and 10-year alendronate therapy,
which is associated with no difference in side effect profiles of short term versus long term
alendronate therapy. Bisphosphonates can lower serum calcium, but this is uncommon without
an underlying vitamin D deficiency (Milat & Ebeling, 2016). Milat and Ebeling found that over
suppression of bone remodeling could lead to microdamage accumulation, which could lead to
increased fragility. Atypical femoral fractures are more common in patients who have been
exposed to long-term bisphosphonate therapy for seven or more years (Milat & Ebeling, 2016).
In conclusion, gastrointestinal symptoms are the most common adverse effects of
alendronate therapy but are not statistically significant compared to placebo therapy. There is
inconclusive evidence of whether the prolonged reduction of bone turnover being the mechanism
for rare adverse events such as ONJ and atypical fractures should be the focus of future research.
Efficacy of Romosozumab, Prototypical Sclerostin Inhibitor, in Postmenopausal Women
Bhattacharyya et al. explain that romosozumab works by both anti-resorptive and
anabolic properties, which were found to increase BMD in postmenopausal women in the lumbar
spine, total hip, and femoral neck. Bone resorption markers in romosozumab treated patients
decreased by 50% below baseline during the first week and remained below the baseline
throughout the 12-month treatment course (Bhattacharyya et al., 2018). Studies performed by
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Bandeira et al., Makras et al., and Ishibashi et al. found similar results that romosozumab
significantly increase bone formation markers along with a statistically significant decrease in
bone resorption markers, all being dose dependent. According to Makras et al., these results are
reported to be considerably higher than those observed in phase II clinical studies for
alendronate. Bandeira et al. concluded that bone formation markers returned to baseline after
nine months of treatment, and bone resorption markers remained below baseline after 12 months
of treatment. Phase III studies showed that after one-year romosozumab showed a 73% reduction
in new vertebral fractures along with a 36% decrease in clinical fractures compared to the
placebo group (Bandeira et al., 2017). After two years of treatment, there was a decrease of 75%
of new vertebral fractures in the romosozumab group compared to placebo but no statistical
difference in clinical fractures between the romosozumab and placebo group (Bandeira et al.,
2017).
Similar results were found by Liu et al. and Ishibashi et al. that romosozumab had a
significantly lower risk of new vertebral fractures, non-vertebral fractures, and hip fractures
compared to placebo and alendronate. BMD was also increased dramatically with romosozumab
versus placebo (Liu et al., 2018) (Horne et al., 2018). The most substantial gains in BMD were
dose-dependent, the highest increase of BMD seen in participants receiving 210 mg monthly
romosozumab injections. Liu et al. also found that treatment with romosozumab after previous
bisphosphonate treatment also showed a significant increase in BMD at the lumbar spine, total
hip, and femoral neck 12 months after switching from bisphosphonate therapy to romosozumab
therapy. Horne et al. reported that BMD after 12 months of romosozumab treatment with an
additional 12 months of denosumab accounted for a 73% retention of treatment benefit, with
similar results were found with total hip BMD treatment retention of 87%. Participants who did
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not receive denosumab after the completion of romosozumab treatment lost 80-90% of BMD
(Horne et al., 2018).
In conclusion, romosozumab significantly increase bone formation and substantially
decreased bone resorption markers, along with significantly increasing BMD. There is also
evidence that treatment with bisphosphonates after the use of romosozumab helps to maintain the
increase in bone density that occurred with romosozumab treatment and that combination
therapy might be the key to treating osteoporosis.
Efficacy of Alendronate, Prototypical Bisphosphonate, in Postmenopausal Women
According to Cesareo et al. and Zhang et al., participants receiving alendronate plus
vitamin D treatment significantly increased BMD from baseline at the lumbar spine, femoral
neck, and total hip compared to the control group, vitamin D alone, which had a significant
decrease in BMD after 12 months. Bone turnover markers significantly decreased in the
alendronate treatment group compared to the control group (Cesareo et al., 2014) (Zhang et al.
2015). Hassler et al. found that iliac crest biopsies from postmenopausal osteoporosis patients
showed that treatment with alendronate for ten years restores bone material indices to
premenopausal non-osteoporotic values. Both alendronate 5-year and 10-year treatment groups
had higher values in both cancellous and cortical bone compared to placebo groups.
This research provides statistically significant data that alendronate plus vitamin D is
superior in increasing BMD than the conservative treatment of vitamin D alone. It also provides
evidence that alendronate therapy continues to increase cancellous and cortical bone even during
an extended length of therapy. This study was conducted longer than 12-24-month therapy time
frames, which most other studies did not.
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Direct Comparison of Romosozumab and Alendronate
According to Ferrari, Khosla, and Liu et al. in both the FRAME and ARCH trial,
romosozumab is superior to alendronate in decreasing new fractures and increasing BMD. These
trials also showed a reduced risk of vertebral fractures and clinical fractures after treatment with
romosozumab which, was significantly more than compared to placebo (Ferrari, 2018) (Liu et
al., 2018). A phase II study by Larsson found that romosozumab is statistically superior to
alendronate in increasing BMD and that biochemical markers for the alendronate group did not
show a significant increase in bone formation marker P1NP and there was no change in the bone
resorption marker βCTX. Song and Lee found that postmenopausal women with osteoporosis
that were treated with romosozumab followed by alendronate had a significantly lower risk of
fracture than participants who only received alendronate.
Liu et al. and Larsson found no significant difference in the incidence of adverse events
in patients treated with romosozumab compared to placebo and alendronate. The ARCH trial
noted that participants who were treated with romosozumab had an increased incidence of severe
cardiovascular events compared to the alendronate treatment group (Ferrari, 2018) (Khosla,
2017). However, Khosla reports that the FRAME trial did not identify any difference between
the cardiovascular adverse events between the romosozumab and the placebo groups. Ferrari
suggests that it remains unclear if this adverse event is related to sclerostin inhibition or if it is
due to the romosozumab treatment group containing an older population, which may have
increased the cardiovascular risk. A systematic review by Song and Lee explains that
romosozumab’s mechanism of action of blocking sclerostin may lead to vascular calcification
and result in arterial stiffening and severe cardiovascular disease. Therefore, advanced
abdominal aortic calcification is more common in patients with vertebral fractures (Song & Lee,
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2018). According to Song and Lee, participants in the ARCH trial likely had more advanced
abdominal aortic calcification before the initiation of the study.
Taking this information into consideration, it is unsure if romosozumab increases
cardiovascular adverse events or if alendronate is cardioprotective. Khosla points out that women
in the ARCH trial were less healthy than women in the FRAME trial. Even with this information,
it is still believed that romosozumab slightly increases the risk of cardiovascular events in
women with multiple co-morbidities. Further research needs to be conducted on the effect
romosozumab has on Wnt signaling, and its role in cardiovascular remodeling and sclerostin
levels are increased at sites of vascular calcification. However, there is clear evidence that
romosozumab is superior to alendronate in increasing BMD, increasing bone-forming markers,
decreasing bone resorption markers, and decreasing fractures rates in postmenopausal women
with osteoporosis.
Applicability to Clinical Practice
With the information in this literature review, the medical provider will be able to make
the most effective and safest decision based solely on evidence-based medicine in the treatment
of osteoporosis in postmenopausal patients. Whether it is primary care or emergency medicine,
osteoporosis will likely be seen daily by most providers due to the number of Americans affected
by this disease. With the USPSTF recommendation of bone density scans in females 65 and
older, many patients will have the diagnosis of osteopenia or osteoporosis. As the population of
the United States continues to grow, and the baby boomer generation is starting to move into the
65 and older category, osteoporosis will begin to become even more prevalent in everyday
healthcare. The Center for Disease Control states that by 2030 older adults, classified as 65 plus,
will account for 20% of the United States population (CDC, 2013). Fractures, as a result of
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osteoporosis, can be debilitating to the patient and the patient’s family/caretakers. Hip fractures
are especially a topic of concern, as hip fractures are associated with a significant financial
burden, increased risk of mortality, and loss of independence. In general, if a patient experiences
a hip fracture, they will lose one level of independence (if they were previously using a cane,
they will now need a walker, then wheelchair, etc.).
It is crucial that we, medical professionals, provide the best evidence-based medicine for
patients with osteoporosis because of the increasing elderly population of the baby boomers and
because of how detrimental a fracture can be to a patient and their family. The research presented
shows there is no “perfect” solution in treating postmenopausal osteoporosis. In general, treating
postmenopausal women with osteoporosis with romosozumab for two years, followed by
bisphosphonate therapy, shows the best evidence for both bone formation and retention of bone
density. However, we, as providers, must weigh the risks and benefits of this treatment regimen,
being extra cautious looking into cardiovascular health issues for patients. It is imperative that
we, as healthcare providers, take a thorough medical history and consider patient preference and
decide in collaboration with the patient about their treatment for osteoporosis.
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